Another batch of drug reviews!

According to relevant national policies, the quality and efficacy of the over-evaluated drugs are equivalent to the original research products, and appropriate support will be given in terms of medical insurance payment and procurement by medical institutions
.
With the advancement of the state's policy of encouraging the preferential purchase and use of reviewed drugs, a large number of pharmaceutical companies have actively invested in consistency evaluation in order to enhance market competitiveness and expand market share, and good news of product review has continued to come
.
Recently, there have been a large number of drug reviews, let's take a look at which drug companies are involved! Shanghai Pharmaceuticals: Review of Flunarizine Hydrochloride Capsules Shanghai Pharmaceuticals announced on March 4 that Shandong Xinyi, a holding subsidiary, received the “Approval Notice for Supplementary Drug Application” issued by the State Food and Drug Administration for Flunarizine Hydrochloride Capsules.
The drug passed the consistency evaluation of generic drugs
.
Flunarizine hydrochloride capsules are mainly used for the preventive treatment of typical (with aura) or atypical (without aura) migraine
.
According to data from Minet.
com, in the first half of 2021, the cumulative sales of flunarizine hydrochloride capsules in public hospitals and grassroots terminals was about 340 million yuan; in the whole year of 2021, the sales of flunarizine hydrochloride capsules in pharmacies were 124 million yuan.
Yuan
.
Up to now, in addition to Shanghai Pharmaceuticals, at least 6 flunarizine hydrochloride capsule manufacturers have passed the consistency evaluation, including Zhendong Pharmaceutical, Shandong Fangming Pharmaceutical, Jiangsu Pingguang Pharmaceutical (Jiaozuo), Huaxin Pharmaceutical, Chia Tai Qingchunbao Pharmaceuticals and Anxin Bio,
etc.
Osaikang: Levobupivacaine Hydrochloride Injection Over-Evaluated Recently, Jiangsu Osaikang Pharmaceutical announced that the company received the "Approval Notice for Supplementary Drug Application" for Levobupivacaine Hydrochloride Injection approved and issued by the State Food and Drug Administration.
The drug was approved to pass the quality and efficacy consistency evaluation of generic drugs
.
According to the announcement, levobupivacaine is a new long-acting amide local anesthetic developed by Abbott, which was approved by China's NMPA in June 2012
.
According to statistics from Minet.
com, in 2018, the sales of levobupivacaine hydrochloride injection in the three major terminal public hospitals in cities, counties and townships in China approached 100 million yuan
.
At present, a number of domestic companies have approved generic drug levobupivacaine hydrochloride injection, including Zhuhai Rundu Pharmaceutical, Jiangsu Hengrui Pharmaceutical, etc..
As early as November 2016, Osaikang was approved to market Levobupivacaine Hydrochloride Injection 10ml:50mg, and in November 2020, it applied for the consistency evaluation of generic drugs, and it was approved recently, becoming the second domestic company to pass the evaluation
.
Wanbonde: Review of Phloroglucinol Injection Wanbonde issued an announcement on the evening of March 1, and its subsidiary Wanbonde Pharmaceutical received the "Approval Notice for Supplementary Drug Application" from the State Food and Drug Administration on Phloroglucinol Injection on the same day , the phloroglucinol injection produced by the company passed the consistency evaluation
.
It is understood that in the field of pharmaceuticals, the company is the first domestically reviewed pharmaceutical company
.
Phloroglucinol can directly act on the smooth muscles of the digestive system, urinary system and reproductive system, and has a large clinical demand.
It has been included in the national medical insurance category B product in 2017
.
According to data from Minet.
com, in the first half of 2020, the market size of phloroglucinol in Chinese public medical institutions exceeded 1 billion yuan
.
At present, only three domestic pharmaceutical companies have the registration approval for phloroglucinol injection and are engaged in the production of the drug
.
The phloroglucinol injection produced by Wanbangde Pharmaceutical obtained the drug approval number in 2018, and was put into the market through GMP certification in April 2019.
This product review will greatly improve the company's products in the hospital market competitiveness.
Increase market share
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.